New U.S. Clinical Studies Provide Further Validation for Aroa Biosurgery's Myriad™, as Products Also Approved for Use in India

Author's Avatar
Dec 16, 2020
Article's Main Image

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) has gained further validation for Myriad™, a device for soft tissue reconstruction, with two studies published in successive months in a leading peer reviewed scientific journal, Journal of Wound Care, official journal of the European Wound Management Association (EWMA) and World Union of Wound Healing Societies (WUWHS).